GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Lecanemab Real-World Safety: Duke Health Study Insights for Alzheimer’s Patients
For decades, the search for a way to slow down Alzheimer’s disease felt like chasing a horizon that never got closer. However, the arrival of anti-amyloid therapies like lecanemab has shifted the conversation from "what if" to "how." While clinical trials provide a controlled environment to test these drugs
Tiny Bubbles, Big Breakthrough: How Exosomes Carry Alzheimer's Treatments Past the Blood–Brain Barrier
Your brain consumes roughly 20% of your body's energy, meaning it relies on a massive network of blood vessels. To protect your central nervous system from harmful chemical swings and infections, the cells lining these blood vessels fit together like microscopic puzzle pieces sealed with airtight biological glue. This tight network is the Blood–Brain Barrier.
The Alzheimer’s Revolution: Simple Blood Tests Spotting Risk Years Before Symptoms
For decades, Alzheimer’s disease has been a silent and elusive adversary. It crawls slowly through the brain, dismantling neural connections and building up toxic protein barriers long before the first lapse in memory occurs. Traditionally, confirming a diagnosis of Alzheimer’s has been a reactive process. Patients and their families had to wait for undeniable symptoms—confusion, forgetfulness, and changes in behavior—before seeking medical confirmation. By the time these symptoms manifest, significant and often irreversible brain damage has already occurred.
AI Brain Map Predicts Early-Onset Alzheimer's Progression
When most people picture Alzheimer's disease, they imagine an individual in their late 70s or 80s gradually experiencing memory loss. However, Early-Onset Alzheimer's Disease (EOAD) paints a starkly different, often heartbreaking picture. Striking individuals under the age of 65—frequently in their 40s or 50s—EOAD attacks people who are at the very peak of their personal and professional lives.
Dementia Risk After 90: New Study Shows Why We're Never In the Clear
It is a common and comforting assumption: if you or your loved ones can make it to 90 years old with a sharp mind, you have somehow beaten the odds. We tend to think that after a certain milestone, the risk of cognitive decline plateaus, and we can finally breathe a sigh of relief.
Estrogen Receptor ERβ: A New Hope in the Fight Against Alzheimer’s in Women
If you look at the statistics for Alzheimer’s disease, one striking detail immediately stands out: almost two-thirds of all people living with Alzheimer's are women. For decades, scientists and doctors explained this gap simply by pointing to the calendar—women
"Lonely Waves" and Genetic Timers: The Latest Alzheimer’s Breakthroughs Decoded
If you opened Google Scholar or picked up the latest issues of Nature Neuroscience or The Lancet Neurology over the past few days, you would spot two huge themes: how our sleep architecture betrays early brain changes, and how combining blood tests with genetics creates an exact clock for when symptoms will start.
The 158-Trial Revolution: Inside the Landmark World Alzheimer Report 2026
For decades, medicine treated dementia as an unyielding natural consequence of aging. But between the massive trial pipeline data released this week, new lipid discoveries from UT Health, and a surge in repurposing existing cardiovascular medications, the paradigm has officially shifted from late-stage symptom management to early multi-target prevention.
Unlocking Clinical Equity: How Glassbury AI Meets FDA Diversity Action Plan Mandates in Alzheimer’s Research
Explore how Glassbury AI uses Google Cloud, MedGemma, and Vertex AI Explainable AI to guarantee FDA Diversity Action Plan compliance and accelerate Alzheimer's clinical trial matching.